VRP Verona Pharma Plc

                               Verona Pharmaplc

                      ("Verona Pharma" or the "Company")

                              Director's Dealing

20 January 2015, Cardiff - Verona Pharma plc (AIM: VRP) yesterday received
notification that on 19 January 2015 Mr Stuart Bottomley, Non-Executive
Director of the Company, purchased via his SIPP 1,000,000 ordinary shares of
0.1p each in the Company ("Ordinary Shares") at a price of 1.5 pence per share.

Following the acquisition, Mr Bottomley will have an interest in the Company of
20,000,000 Ordinary Shares, representing 1.98% of the Company's issued ordinary
share capital.

                                    -Ends-

For further information please contact:

Verona Pharma plc                       Tel: +44 (0) 20 3283 4200

Jan-Anders Karlsson, CEO

N+1 Singer                              Tel: +44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

FTI Consulting                          Tel: +44 (0)20 3727 1000

Julia Phillips / Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company
focused on the development of innovative prescription medicines to treat
respiratory diseases with significant unmet medical needs, such as COPD, asthma
and cystic fibrosis. Verona Pharma's lead drug, RPL554, is a first-in-class
drug currently in Phase II trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential to the
improvement of patients with COPD and asthma. Verona Pharma is also building a
broader franchise around RPL554 to maximise its value, both to patients and to
investors. This includes the very significant markets for COPD and asthma
maintenance therapy. The Company is also exploring the potential of the drug in
different diseases, such as cystic fibrosis, where it is in pre-clinical
testing.